BID | 7.32 | ASK | 7.95 | ||
Open | 7.80 | Previous Close | 7.75 | ||
Pre-Market | - | After-Market | 7.70 | ||
- - | 0.04 0.52% |
Target Price | 28.00 | Analyst Rating | Moderate Buy 2.29 | |
Potential % | 265.54 | Finscreener Ranking | ★★★★+ 56.89 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-91 | Value Ranking | ★★★★ 57.22 | |
Insiders Value % 3/6/12 mo. | -100/-100/-95 | Growth Ranking | ★★★★ 57.91 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-94 | Income Ranking | — - | |
Price Range Ratio 52W % | 9.94 | Earnings Rating | Strong Sell | |
Market Cap | 414.93M | Earnings Date | 2nd Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.17 | |
Beta | 0.95 |
Today's Price Range 7.557.83 | 52W Range 6.2220.71 | 5 Year PE Ratio Range -93.20-3.00 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -3.28% | ||
1 Month | -12.66% | ||
3 Months | -2.79% | ||
6 Months | -13.25% | ||
1 Year | -51.74% | ||
3 Years | -75.53% | ||
5 Years | -70.48% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -10.06 | |||
ROE last 12 Months | -17.79 | |||
ROA (5Y Avg) | -2.62 | |||
ROA last 12 Months | -14.57 | |||
ROC (5Y Avg) | -55.67 | |||
ROC last 12 Months | -15.73 | |||
Return on invested Capital Q | -3.76 | |||
Return on invested Capital Y | -3.30 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 3.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-8.00 | ||||
1.38 | ||||
2.65 | ||||
1.43K | ||||
-10.50 | ||||
-0.53 | ||||
1.69 | ||||
8.16 | ||||
350.40M | ||||
Forward PE | -3.77 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.10 | ||||
5.50 | ||||
0.07 | ||||
0.09 | ||||
- | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
65.60 | ||||
-23.10 | ||||
-18.40 | ||||
-46.40 | ||||
-24.34 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
239.41M | ||||
4.47 | ||||
44.98 | ||||
48.20 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.56 | -0.46 | 17.86 |
Q01 2023 | -0.32 | -0.44 | -37.50 |
Q04 2022 | -0.36 | -0.34 | 5.56 |
Q03 2022 | -0.41 | -0.32 | 21.95 |
Q02 2022 | -0.30 | -0.41 | -36.67 |
Q01 2022 | -0.30 | -0.37 | -23.33 |
Q04 2021 | -0.19 | -0.31 | -63.16 |
Q03 2021 | -0.14 | -0.23 | -64.29 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.67 | -63.41 | Negative |
12/2023 QR | -0.61 | -96.77 | Negative |
12/2023 FY | -2.21 | -38.99 | Negative |
12/2024 FY | -2.10 | -107.92 | Negative |
Next Report Date | 2nd Nov 2023 |
Estimated EPS Next Report | -0.67 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 400.60K |
Shares Outstanding | 54.17K |
Shares Float | 48.54M |
Trades Count | 5.94K |
Dollar Volume | 3.08M |
Avg. Volume | 741.10K |
Avg. Weekly Volume | 786.08K |
Avg. Monthly Volume | 607.24K |
Avg. Quarterly Volume | 829.97K |
CareDx Inc. (NASDAQ: CDNA) stock closed at 7.66 per share at the end of the most recent trading day (a -1.16% change compared to the prior day closing price) with a volume of 400.60K shares and market capitalization of 414.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 475 people. CareDx Inc. CEO is Reginald Seeto.
The one-year performance of CareDx Inc. stock is -51.74%, while year-to-date (YTD) performance is -32.87%. CDNA stock has a five-year performance of -70.48%. Its 52-week range is between 6.2202 and 20.71, which gives CDNA stock a 52-week price range ratio of 9.94%
CareDx Inc. currently has a PE ratio of -8.00, a price-to-book (PB) ratio of 1.38, a price-to-sale (PS) ratio of 2.65, a price to cashflow ratio of 1 429.20, a PEG ratio of -, a ROA of -14.57%, a ROC of -15.73% and a ROE of -17.79%. The company’s profit margin is -24.34%, its EBITDA margin is -18.40%, and its revenue ttm is $239.41 Million , which makes it $4.47 revenue per share.
Of the last four earnings reports from CareDx Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. CareDx Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for CareDx Inc. is Moderate Buy (2.29), with a target price of $28, which is +265.54% compared to the current price. The earnings rating for CareDx Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CareDx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CareDx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.93, ATR14 : 0.45, CCI20 : -112.92, Chaikin Money Flow : -0.17, MACD : -0.42, Money Flow Index : 22.20, ROC : -13.05, RSI : 34.61, STOCH (14,3) : 7.59, STOCH RSI : 0.00, UO : 36.33, Williams %R : -92.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CareDx Inc. in the last 12-months were: Bickerstaff George (Option Excercise at a value of $99 065), George W. Bickerstaff (Option Excercise at a value of $18 300), Maag Peter (Sold 2 432 shares of value $21 216 ), Peter Maag (Sold 10 701 shares of value $158 558 ), Reginald Seeto (Sold 54 407 shares of value $675 304 ), Seeto Reginald (Sold 19 905 shares of value $180 905 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey, and is a leading provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden.
CEO: Reginald Seeto
Telephone: +1 415 287-2300
Address: 1 Tower Place, South San Francisco 94080, CA, US
Number of employees: 475
Mon, 07 Aug 2023 12:55 GMT CareDx (CDNA) Gets a Hold from Craig-Hallum
- TipRanks. All rights reserved.Tue, 11 Jul 2023 13:10 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: CareDx (CDNA), Omnicell (OMCL) and Xtant Medical Holdings (XTNT)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.